Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 203

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

Ben-Horin, S., Yavzori, M., Katz, L., Kopylov, U., Picard, O., Fudim, E., Coscas, D., Bar-Meir, S., Goldstein, I., Chowers, Y. · 2011 · Gut

Abstract

OBJECTIVES: To localise the immunogenic part of infliximab and evaluate the clinical usefulness of measuring antibodies against infliximab fragments. DESIGN: Observational study. SETTINGS: A specialised inflammatory bowel disease (IBD) centre in a tertiary hospital. INTERVENTIONS: Serum was collected from patients with IBD and controls. Antibodies against whole infliximab (ATI) and against the digested Fc, F(ab')(2) and F(ab') fragments were measured by a specifically developed ELISA and by western blotting. A separate ELISA was used to determine infliximab levels in serum. RESULTS: 109 serum samples from 62 infliximab-treated patients were tested along with 64 control samples. Anti-F(ab')(2) antibodies were found in 28/42 (67%) samples with positive ATI, all from infliximab-exposed patients. Anti-F(ab')(2) antibodies were also present in 26 of the remaining 67 (39%) samples from exposed patients despite absent ATI. No specific anti-Fc antibodies were detected. Low trough infliximab level and high ATI level was found in 10/12 patients (83%) with complete loss of response to infliximab, but in only 5/14 patients (36%, p=0.02) who regained response to intensified infliximab regimen and in 2/24 patients (8%, p<0.001) in maintained remission while on 5 mg/kg/8 week infliximab treatment. Although Anti-F(ab')(2) antibodies showed similar test characteristics to ATI in patients losing response to infliximab, they were also detected in 61% of patients in maintained remission, thereby limiting their clinical usefulness. No cross reactivity to adalimumab was noted. CONCLUSIONS: F(ab')(2) is the immunogenic fragment of infliximab. However, ATI level in serum--combined with measurement of trough infliximab level--is better correlated with the clinical response to infliximab or with its loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gut.2009.201533

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 203

Metadata

Authors
Ben-Horin, S., Yavzori, M., Katz, L., Kopylov, U., Picard, O., Fudim, E., Coscas, D., Bar-Meir, S., Goldstein, I., & Chowers, Y.
Venue
Gut
Publisher
BMJ
Published
2010-06-02
Volume
60
Issue
1
Pages
41-48
ISSN
0017-5749 (ISSN-L)
OpenAlex
W2134803931
Cited by
203
References
1
FWCI
7.54
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. https://app.cochat.ai/papers/10.1136/gut.2009.201533
The paper
Ben-Horin, S., Yavzori, M., Katz, L., Kopylov, U., Picard, O., Fudim, E., Coscas, D., Bar-Meir, S., Goldstein, I., & Chowers, Y. (2011). The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. https://doi.org/10.1136/gut.2009.201533

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.